Full Title
GSK 220752: A Phase 2 Open-Label Study to Evaluate Momelotinib in Combination with Luspatercept in Participants with Transfusion Dependent Primary or Secondary MyelofibrosisPurpose
Myelofibrosis is a rare disease known as a myeloproliferative neoplasm. The bone marrow becomes scarred and cannot make enough blood cells, leading to anemia. Anemia is low number of red blood cells, causing tiredness and shortness of breath.
Some people with myelofibrosis need regular transfusions of blood. In this study, researchers want to see if momelotinib given with luspatercept reduces the need for blood transfusions in these patients.
Momelotinib works by blocking two proteins called JAK and ACVR1. When JAK proteins send too many signals, the body makes the wrong amount of blood cells. By blocking JAK, momelotinib may help your body make the right amount of blood cells. By targeting ACVR1, momelotinib may fight anemia. Momelotinib is taken orally (by mouth).
By improving red blood cell development, luspatercept may reduce the need for blood transfusions in people with transfusion-dependent myelofibrosis. Luspatercept is given by an injection under the skin.
Who Can Join
To join this study, there are a few conditions. You must:
- Have transfusion-dependent myelofibrosis and not be planning to have a stem cell transplant.
-
Have completed prior anti-myelofibrosis treatments at least 4 weeks before getting the study therapy.
-
Have not received momelotinib or luspatercept in the past.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information about this study or to see if you can join, please call Dr. Brian Chernak’s office at 646-608-4366.
Protocol
25-298
Phase
Phase II (phase 2)
Disease Status
Newly Diagnosed & Relapsed/Refractory
Investigator
Co-Investigators
ClinicalTrials.gov ID
NCT06517875